Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fidaxomicin DDI with Rosuvastatin in Healthy Males
NCT02083627Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2013
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fidaxomicin in Clostridium difficile infection (CDI) (2 arms), sponsored by Astellas Pharma. Primary endpoints: Maximum Observed Concentration and Area Under the Concentration Time Curve. Started Feb 2013; status: completed.
02
Drugs
fidaxomicin
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT02083627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083627.